311 related articles for article (PubMed ID: 30945531)
1. Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors.
Liu R; Yue Z; Tsai CC; Shen J
J Am Chem Soc; 2019 Apr; 141(16):6553-6560. PubMed ID: 30945531
[TBL] [Abstract][Full Text] [Related]
2. Targeting protein kinases with selective and semipromiscuous covalent inhibitors.
Miller RM; Taunton J
Methods Enzymol; 2014; 548():93-116. PubMed ID: 25399643
[TBL] [Abstract][Full Text] [Related]
3. Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.
Zhao Z; Liu Q; Bliven S; Xie L; Bourne PE
J Med Chem; 2017 Apr; 60(7):2879-2889. PubMed ID: 28326775
[TBL] [Abstract][Full Text] [Related]
4. The Cysteinome of Protein Kinases as a Target in Drug Development.
Chaikuad A; Koch P; Laufer SA; Knapp S
Angew Chem Int Ed Engl; 2018 Apr; 57(16):4372-4385. PubMed ID: 28994500
[TBL] [Abstract][Full Text] [Related]
5. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.
Rao S; Gurbani D; Du G; Everley RA; Browne CM; Chaikuad A; Tan L; Schröder M; Gondi S; Ficarro SB; Sim T; Kim ND; Berberich MJ; Knapp S; Marto JA; Westover KD; Sorger PK; Gray NS
Cell Chem Biol; 2019 Jun; 26(6):818-829.e9. PubMed ID: 30982749
[TBL] [Abstract][Full Text] [Related]
6. Profiling MAP kinase cysteines for targeted covalent inhibitor design.
Liu R; Verma N; Henderson JA; Zhan S; Shen J
RSC Med Chem; 2022 Jan; 13(1):54-63. PubMed ID: 35224496
[TBL] [Abstract][Full Text] [Related]
7. How Reactive are Druggable Cysteines in Protein Kinases?
Awoonor-Williams E; Rowley CN
J Chem Inf Model; 2018 Sep; 58(9):1935-1946. PubMed ID: 30118220
[TBL] [Abstract][Full Text] [Related]
8. Developing irreversible inhibitors of the protein kinase cysteinome.
Liu Q; Sabnis Y; Zhao Z; Zhang T; Buhrlage SJ; Jones LH; Gray NS
Chem Biol; 2013 Feb; 20(2):146-59. PubMed ID: 23438744
[TBL] [Abstract][Full Text] [Related]
9. Reactive Chemical Probes: Beyond the Kinase Cysteinome.
Jones LH
Angew Chem Int Ed Engl; 2018 Jul; 57(30):9220-9223. PubMed ID: 29644769
[TBL] [Abstract][Full Text] [Related]
10. Lysine-Targeted Inhibitors and Chemoproteomic Probes.
Cuesta A; Taunton J
Annu Rev Biochem; 2019 Jun; 88():365-381. PubMed ID: 30633551
[TBL] [Abstract][Full Text] [Related]
11. Selectively Targeting the Kinome-Conserved Lysine of PI3Kδ as a General Approach to Covalent Kinase Inhibition.
Dalton SE; Dittus L; Thomas DA; Convery MA; Nunes J; Bush JT; Evans JP; Werner T; Bantscheff M; Murphy JA; Campos S
J Am Chem Soc; 2018 Jan; 140(3):932-939. PubMed ID: 29232121
[TBL] [Abstract][Full Text] [Related]
12. Reversible lysine-targeted probes reveal residence time-based kinase selectivity.
Yang T; Cuesta A; Wan X; Craven GB; Hirakawa B; Khamphavong P; May JR; Kath JC; Lapek JD; Niessen S; Burlingame AL; Carelli JD; Taunton J
Nat Chem Biol; 2022 Sep; 18(9):934-941. PubMed ID: 35590003
[TBL] [Abstract][Full Text] [Related]
13. The resistance tetrad: amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles.
Bailey FP; Andreev VI; Eyers PA
Methods Enzymol; 2014; 548():117-46. PubMed ID: 25399644
[TBL] [Abstract][Full Text] [Related]
14. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).
Roskoski R
Pharmacol Res; 2021 Mar; 165():105422. PubMed ID: 33434619
[TBL] [Abstract][Full Text] [Related]
15. Reactivities of the Front Pocket N-Terminal Cap Cysteines in Human Kinases.
Liu R; Zhan S; Che Y; Shen J
J Med Chem; 2022 Jan; 65(2):1525-1535. PubMed ID: 34647463
[TBL] [Abstract][Full Text] [Related]
16. New insights in protein kinase conformational dynamics.
Saladino G; Gervasio FL
Curr Top Med Chem; 2012; 12(17):1889-95. PubMed ID: 23116468
[TBL] [Abstract][Full Text] [Related]
17. Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.
Kwarcinski FE; Brandvold KR; Phadke S; Beleh OM; Johnson TK; Meagher JL; Seeliger MA; Stuckey JA; Soellner MB
ACS Chem Biol; 2016 May; 11(5):1296-304. PubMed ID: 26895387
[TBL] [Abstract][Full Text] [Related]
18. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
[TBL] [Abstract][Full Text] [Related]
19. Modeling conformational flexibility of kinases in inactive states.
Schwarz D; Merget B; Deane C; Fulle S
Proteins; 2019 Nov; 87(11):943-951. PubMed ID: 31168936
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families.
Li L; Meyer C; Zhou ZW; Elmezayen A; Westover K
J Mol Biol; 2022 Sep; 434(17):167626. PubMed ID: 35595166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]